InsiderTrades

Form 4 for PYXS Pyxis Oncology, Inc.

Accepted 2021-10-15 00:00:00 ET · period of report 2021-10-13 · accession 0001578563-21-000038 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-10-15 2021-10-13 PYXS Bayer World Investments B.V. Former 10% Owner C - Cnv Deriv — +2.74M 2.74M New —
DM 2021-10-15 2021-10-13 PYXS Bayer World Investments B.V. Former 10% Owner C - Cnv Deriv — -17.44M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-10-13 C A 2,742,338 — 2,742,338 D — — (F1) Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. (F2) The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
2 Derivative Series A Convertible Preferred Stock 2021-10-13 C D 11,362,462 — 0 D — · — to — 1,786,831 Common Stock (F1) Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. (F2) The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
3 Derivative Series B Convertible Preferred Stock 2021-10-13 C D 6,076,072 — 0 D — · — to — 955,507 Common Stock (F1) Shares of Series A and Series B Convertible Preferred Stock converted into shares of the Issuer's common stock at the closing of the Issuer's initial public offering at a 6.359-for-1 conversion ratio for no additional consideration (except for the payment in cash in lieu of any fractional shares), and had no expiration date. (F2) The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.